Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome - 18/06/18
, Karen Pieper, MS a, Daniel M. Wojdyla, MS a, Manesh R. Patel, MD a, William Schuyler Jones, MD a, Pierluigi Tricoci, MD a, Kenneth W. Mahaffey, MD b, c, Stefan K. James, MD, PhD d, John H. Alexander, MD, MHS a, Renato D. Lopes, MD, PhD a, Lars Wallentin, MD, PhD d, Erik Magnus Ohman, MD a, Matthew T. Roe, MD, MHS a, Sreekanth Vemulapalli, MD aAbstract |
Background |
Patients with peripheral artery disease (PAD) are known to have an increased risk of ischemic cardiovascular events. However, the influence of concomitant PAD on first and subsequent recurrent ischemic events after an acute coronary syndrome (ACS) remains poorly characterized.
Methods |
We analyzed the combined data set from 4 randomized trials (PLATO, APPRAISE-2, TRA-CER, and TRILOGY ACS) in ACS for a follow-up length of 1 year. Using multivariable regression, we examined the association between PAD and major adverse cardiovascular events, a composite of cardiovascular death, myocardial infarction, and stroke. Among patients with a nonfatal first event, we evaluated the incidence and type of a second recurrent event.
Results |
A total of 4,098 of 48,094 (8.5%) post-ACS patients had a history of PAD. The unadjusted frequency of major adverse cardiovascular events was 2-fold higher in patients with PAD (14.3% vs 7.5%) over a median (25th-75th) follow-up of 353 (223-365) days with an adjusted hazard ratio of 1.63 (95% CI: 1.48-1.78; P < .001). The frequency of recurrent ischemic events among those patients with a first, nonfatal event was higher among those with PAD (40.0% vs 27.7%). The relative frequency of each event type (cardiovascular death, noncardiovascular death, myocardial infarction, or stroke) within first and subsequent ischemic events was similar regardless of PAD status at baseline.
Conclusions |
Patients with PAD have a significantly higher risk of first and recurrent ischemic events in the post-ACS setting. These findings highlight the opportunity for improved treatments in patients with PAD who experience an ACS.
Le texte complet de cet article est disponible en PDF.Plan
| Toru Suzuki, MD, served as guest editor for this article. |
|
| Clinical Trial Registration: ClinicalTrials.gov: PLATO, NCT00391872; APPRAISE-2, NCT00831441; TRACER, NCT00527943; TRILOGY ACS, NCT00699998. |
Vol 201
P. 25-32 - juillet 2018 Retour au numéro
Article précédent
- The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients
- Daniel J. Friedman, Marat Fudim, Robert Overton, Linda K. Shaw, Divyang Patel, Sean D. Pokorney, Eric J. Velazquez, Sana M. Al-Khatib
- Genetic burden and associations with adverse neurodevelopment in neonates with congenital heart disease
- Gillian M. Blue, Eddie Ip, Karen Walker, Edwin P. Kirk, Alison Loughran-Fowlds, Gary F. Sholler, Sally L. Dunwoodie, Richard P. Harvey, Eleni Giannoulatou, Nadia Badawi, David S. Winlaw
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?